Limited Offer
Biomarkers in Bipolar Disorders
- 1st Edition - January 16, 2022
- Editors: Rodrigo Machado-Vieira, Jair Soares
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 3 9 8 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 3 9 9 - 5
Biomarkers in Bipolar Disorders summarizes cutting-edge findings in biomarkers' research, emphasizing the most promising findings, tools and technologies relevant to drug developme… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBiomarkers in Bipolar Disorders summarizes cutting-edge findings in biomarkers' research, emphasizing the most promising findings, tools and technologies relevant to drug development and personalized medicine. Key findings cover different levels of evidence such as genes, molecules, cells, systems, brain and behavior related to diagnosis (state and trait/endophenotypes), prediction of treatment response and follow-up outcomes, along with the most promising perspectives in each area. Each section includes a comprehensive and focused overview on the state-of-the-art and perspectives. The book concludes with a section on practical applications, encompassing diagnostics development (genetic testing, biomarkers), and new drug development.
Edited by Dr. Rodrigo Machado-Vieira and Dr. Jair C. Soares, and contributed by leading experts in the field of biomarker research, this book will be become the leading tool for all researchers and clinicians in Bipolar Disorder.
- Describes strategies for the biomarker discovery of relevant proteins differentially expressed in Bipolar Disorder
- Presents techniques and main findings in transcriptome research related to CNS synaptic function
- Provides an overview on current behavioral strategies and their validity in drug development in Bipolar Disorder
- Discusses current genetic findings, integrating tests for treatments leading to personalized treatments
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Preface
- Chapter 1. Biomarkers in bipolar disorder: an overview
- Abstract
- 1.1 Introduction
- 1.2 Biomarker definition and rationale for biomarkers in bipolar disorder
- 1.3 Biomarker categories and potential uses in bipolar disorder
- 1.4 Biomarkers in bipolar disorder: current limitations
- 1.5 Future directions in the field of biomarkers in bipolar disorder
- 1.6 Conclusion
- References
- Chapter 2. Neural biomarkers of suicidal behavior: from cognition and circuits to cells (and back)
- Abstract
- 2.1 Neurocognitive studies of suicidal behavior
- 2.2 Postmortem brain research: exploring the cellular and molecular roots of suicide
- Acknowledgment
- References
- Chapter 3. Metabolomics of bipolar disorder
- Abstract
- 3.1 Metabolomics in psychiatric disorders
- 3.2 Biomarkers in bipolar disorder
- 3.3 Metabolomics in bipolar disorder
- 3.4 Future directions of metabolomics as a tool for biomarker discovery and clinical implications
- References
- Chapter 4. Behavioral models of bipolar disorder
- Abstract
- 4.1 Background
- 4.2 Animal models of mania
- 4.3 Mania-like behavior assessment in animals
- 4.4 Animal models of depression
- 4.5 Depressive-like behavior assessment in animals
- 4.6 Conclusions and future directions
- References
- Chapter 5. Structural neuroimaging markers in bipolar disorder
- Abstract
- 5.1 Introduction
- 5.2 Biomarker concepts and neuroimaging markers in psychiatry
- 5.3 Structural neuroimaging in psychiatry
- 5.4 Neuroimaging as a tool to improve the diagnostic accuracy of bipolar disorder
- 5.5 Neuroimaging markers in high-risk populations
- 5.6 Summary and conclusions
- References
- Chapter 6. Magnetic Resonance Spectroscopy in Bipolar Disorder
- Abstract
- 6.1 Background
- 6.2 Proton magnetic resonance spectroscopy
- 6.3 Metabolite abnormalities in bipolar disorder
- 6.4 Brain regions involved in cognitive and affective regulation
- 6.5 Conclusion and future directions
- References
- Further reading
- Chapter 7. Precision psychiatry in bipolar disorder
- Abstract
- 7.1 Introduction
- 7.2 Diagnosis and differential diagnosis
- 7.3 Prognosis prediction
- 7.4 Suicidality prediction
- 7.5 Treatment selection
- 7.6 Supervised and unsupervised learning
- 7.7 Conclusion
- References
- Chapter 8. Genome-wide association study biomarkers in bipolar disorder
- Abstract
- 8.1 Introduction
- 8.2 Generic epidemiology: heritability and family studies
- 8.3 Genome-wide association studies
- 8.4 Recent results of genome-wide association studies in bipolar disorder
- 8.5 Fine mapping: from loci to genes
- 8.6 Common variant heritability and coheritability
- 8.7 Polygenic risk scores
- 8.8 Missing heritability
- 8.9 Genome-wide association studies and treatment of bipolar disorder (pharmacogenetics)
- 8.10 Challenges and opportunities for the next era of genome-wide association studies in bipolar disorder
- 8.11 Conclusions
- References
- Chapter 9. Mitochondrial dysfunction in bipolar disorder
- Abstract
- 9.1 Introduction
- 9.2 Proposal of mitochondrial hypothesis
- 9.3 Cellular models
- 9.4 Cerebrospinal fluid
- 9.5 Genetics
- 9.6 Postmortem brains
- 9.7 Animal models
- 9.8 Drug discovery research
- 9.9 iPS cell model
- 9.10 Molecular and cellular pathogenesis in the paraventricular thalamic nucleus (PVT) and action mechanisms of antibipolar drugs
- 9.11 Neural circuits around the paraventricular thalamic nucleus (PVT)
- 9.12 Conclusion
- Acknowledgments
- References
- Chapter 10. Mechanisms of aging in bipolar disorder
- Abstract
- 10.1 Introduction
- 10.2 Cellular senescence and telomere attrition in bipolar disorder
- 10.3 Epigenetic alterations, DNA damage, and genomic instability
- 10.4 Mitochondria dysfunction
- 10.5 Altered intercellular communication
- 10.6 Concluding remarks
- References
- Chapter 11. Neuroprogression in bipolar disorder
- Abstract
- 11.1 Introduction
- 11.2 Clinical evidence of neuroprogression
- 11.3 Biological basis of neuroprogression
- 11.4 Future perspectives of the field
- 11.5 Conclusions
- References
- Chapter 12. Neuroimmune pathways in bipolar disorder
- Abstract
- 12.1 On the search for the “black bile”
- 12.2 Immune system: an overview
- 12.3 Evidence of immune dysfunction in bipolar disorder
- 12.4 Immune (cerebrospinal fluid and blood) markers of diagnosis in other psychiatric conditions (major depressive disorder and schizophrenia)
- 12.5 Integrating immune dysfunction with the pathogenesis, physiopathology, and prognosis of bipolar disorder
- 12.6 Immune-based strategies for bipolar disorder
- 12.7 Immune markers as predictors of treatment mood response
- 12.8 Conclusion
- References
- Chapter 13. Glutamate-based preclinical and clinical dysfunction and treatment in bipolar disorder
- Abstract
- 13.1 Preclinical
- 13.2 Clinical
- 13.3 Treatment
- 13.4 Conclusion
- References
- Chapter 14. Neurocognitive endophenotypes in bipolar disorders
- Abstract
- 14.1 Cognitive dysfunctions in bipolar disorders
- 14.2 Impact of cognitive dysfunctions in bipolar disorders
- 14.3 Concept of endophenotypes
- 14.4 Neurocognitive endophenotypes in bipolar disorders
- 14.5 Conclusion
- References
- Chapter 15. DNA methylation in bipolar disorder
- Abstract
- 15.1 Introduction
- 15.2 DNA methylation and bipolar disorder diagnosis
- 15.3 DNA methylation and treatment response in bipolar disorder
- 15.4 DNA methylation and animal and preclinical model studies of bipolar disorder
- 15.5 Summary
- References
- Chapter 16. Biomarkers of lithium efficacy in bipolar disorders
- Abstract
- 16.1 Lithium’s efficacy
- 16.2 Biomarkers of lithium prophylaxis efficacy
- 16.3 Biomarkers for lithium efficacy in acute mood episodes
- 16.4 Conclusions
- References
- Chapter 17. Neuroendocrine and stress pathways in bipolar disorders
- Abstract
- 17.1 Introduction
- 17.2 The hypothalamus–pituitary–adrenal axis
- 17.3 Steroid hormones
- 17.4 Mineralocorticoid receptors and glucocorticoid receptors
- 17.5 Neuroendocrine function test
- 17.6 Impact of stress on bipolar disorders
- 17.7 Conclusion
- References
- Chapter 18. Intracellular signaling cascades in bipolar disorder
- Abstract
- 18.1 Introduction
- 18.2 Calcium signaling
- 18.3 Diacylglycerol and protein kinase C pathways
- 18.4 GSK3-β and Wnt pathways
- 18.5 Brain-derived neurotrophic factor
- 18.6 Mitochondrial dysfunction
- 18.7 Conclusion
- References
- Chapter 19. Circadian biomarkers of bipolar disorder
- Abstract
- 19.1 Biomarkers of bipolar disorder
- 19.2 Objectively measured sleep, activity, and circadian rhythms
- 19.3 Endophenotypes for bipolar disorder
- 19.4 Summary, challenges, and opportunities for future research
- Acknowledgments
- References
- Chapter 20. DNA damage and repair mechanisms in bipolar disorder
- Abstract
- 20.1 Introduction
- 20.2 Oxidative stress and its relevance to bipolar disorder
- 20.3 DNA damage and repair mechanisms
- 20.4 DNA damage markers in bipolar disorder
- 20.5 Quantification of 8-oxo-dG in bipolar disorder
- 20.6 DNA damage and affective states of bipolar disorder
- 20.7 DNA repair markers in bipolar disorder
- 20.8 Future directions
- References
- Chapter 21. Microbiome and bipolar disorder
- Abstract
- 21.1 The microbiota-gut-brain axis: a new approach in bipolar disorder biomarkers
- 21.2 The microbiota-gut-brain axis
- 21.3 Microbiota-gut-brain axis and bipolar disorder: gut microbiota as a potential biomarker for bipolar disorder
- 21.4 Main limitations of current research on microbiota-gut-brain axis and bipolar disorder
- 21.5 Conclusions and future directions
- References
- Chapter 22. Inflammation, stress, and gut-brain axis as therapeutic targets in bipolar disorder
- Abstract
- 22.1 Introduction
- 22.2 Gastrointestinal dysfunction and inflammation
- 22.3 Gastrointestinal dysfunction in psychiatric disorders
- 22.4 What is the human gut microbiota?
- 22.5 The microbiome-gut-brain axis
- 22.6 Microbiome-gut-brain-axis findings in neuropsychiatric disorders
- 22.7 Human studies
- 22.8 Bipolar disorder
- 22.9 Treatment
- 22.10 Conclusion and future directions
- References
- Chapter 23. Bipolar disorder and plasticity: a key target for new treatment
- Abstract
- 23.1 Introduction
- 23.2 Concepts of plasticity and implications in bipolar disorder
- 23.3 Cellular studies
- 23.4 Neuroimaging studies
- 23.5 Drugs development targeting GSK-3β
- 23.6 Summary
- References
- Chapter 24. Proteomic biomarkers for bipolar disorder
- Abstract
- 24.1 Introduction
- 24.2 The development of proteomic techniques
- 24.3 Proteome characterization of the peripheral blood
- 24.4 Current status
- 24.5 Differentially abundant proteins
- 24.6 Biological processes and pathways
- 24.7 The future of “OMICS”
- 24.8 Future directions
- References
- Further reading
- Chapter 25. Pharmacogenomics in bipolar disorder: towards precision psychiatry and personalized treatment
- Abstract
- 25.1 Background
- 25.2 Pharmacogenomics and genetic variation
- 25.3 Pharmacokinetic: drug metabolism
- 25.4 Pharmacogenomics of drugs commonly used in bipolar disorder
- 25.5 Future directions for the field
- References
- Index
- No. of pages: 528
- Language: English
- Edition: 1
- Published: January 16, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780128213988
- eBook ISBN: 9780128213995
RM
Rodrigo Machado-Vieira
JS